Dr. Kishore R. Alugupalli, PhD
Founder & CEO TurboVax Inc
Dr. Alugupalli is an internationally recognized immunologist whose research has advanced our understanding of B-cell biology, bacterial immunity, glycoconjugate vaccines, and innate immune regulation. Over a scientific career spanning more than three decades in academia, he has led NIH-funded research, published extensively in leading scientific journals, and developed the Turbo platform technology to address a fundamental challenge in bacterial glycoconjugate vaccine design. His vision for TurboVax is to transform mechanistic immunology into practical vaccine technologies that improve human health worldwide.
Scientific Advisory Board
TurboVax is advised by internationally recognized leaders whose expertise spans immunology, vaccinology, bacterial pathogenesis, clinical medicine, and translational science.
Dr. Tasuku Honjo, MD PhD
Deputy Director-General and Distinguished Professor
Institute for Advanced Study, Kyoto University, Japan
Nobel Prize in Physiology or Medicine in 2018
Dr. Honjo is well known for his discovery of activation-induced cytidine deaminase (AID) that is essential for the antibody class switch recombination and somatic hypermutation. Dr. Honjo discovered PD-1 (program cell death 1), a negative coreceptor at the effector phase of immune response and demonstrated that PD-1 inhibition contributes to cancer treatments. Anti-PD-1 cancer immunotherapy is highly effective has been approved in US, EU, and Japan to treat various cancers. This work lead to his Nobel Prize in Physiology or Medicine in 2018.
Dr. Andreas Bäumler, PhD
Professor and Vice Chair of Medical Microbiology and Immunology
University of California School of Medicine, Davis, CA
Dr. Bäumler’s research program investigates mechanisms of intestinal colonization and the host response to Salmonella infection. Dr. Bäumler is an elected member of the American Academy of Microbiology, the German National Academy of Sciences, the United States National Academy of Sciences, and American Association for the Advancement of Science. Won the prestigious Robert Koch prize in 2021 for his outstanding work in bacterial pathogenesis, how our own gut microbiome works and host defense mechanisms.
Dr. Dieter Schifferli, DVM, PhD
Professor of Microbiology Emeritus
University of Pennsylvania, Philadelphia, PA
Over 40 years of experience in bacterial pathogenesis, with emphasis on bacterial ligands that bind to specific host receptors and mediate bacterial colonization, host cell signaling, and/or optimal toxin delivery. Dr Schifferli also focuses his research on vaccines based on bacterial adhesisns to prevent infections caused by human and veterinary bacterial pathogens.
Dr. Katherine Fitzgerald, PhD
Professor and Vice Chair of Medicine
UMass Chan Medical School, Worcester, MA
Chief of the Division of Innate Immunity. Dr. Fitzgerald's work is focused on the innate immune system aimed at understanding the molecular basis of the inflammatory response during Infection and in inflammatory diseases. Her work has a major impact on our current understanding on how immune system works. Dr. Fitzgerald is an elected member of the American Society of Microbiology, the Royal Irish Academy, and the United States National Academy of Sciences.
Dr. Gordon Dougan, PhD, FRS
Professor, Department of Medicine, University of Cambridge, United Kingdom
Board member Wellcome Sanger Institute, Cambridge, United Kingdom
Dr. Dougan has pioneered work on enteric diseases and been heavily involved in the movement to improve vaccine usage in developing countries. In this regard he was voted as one of the top ten most influential people in the vaccine world by people working in the area. Dr. Dougan is a trustee of the International Vaccine Institute, Korea and has worked with other global agencies including the World Health Organization and the Global Alliance for Vaccine and Innovations (now GAVI Alliance). Dr. Dougan is an elected member of the European Molecular Biology Organization, Fellow of the Academy of Medical Sciences and Fellow of the Royal Society.
Clinical, Regulatory & Business Advisors
TurboVax benefits from experienced advisors who provide guidance across clinical development, regulatory strategy, manufacturing, commercialization, and strategic partnerships.
Dr. Stephen J. McGeady, MD
Pediatrician and Physician Scientist
Nemours Children's Health, Philadelphia, PA
A highly accomplished, board-certified and practicing pediatrician with over 50 years experience in treating children with primary immune deficiencies, impaired vaccine responses, and allergy. As a physician scientist identified many genetic abnormalities in children with altered immune responses that paved our understanding of many childhood diseases.
Dr. Rajesh K. Gupta, PhD
CEO, Biologics Quality & Regulatory Consultants LLC
Gaithersburg, MD, USA
Over 40 years’ experience in the development, production, testing, and regulation of vaccines. At FDA, he formed the Division of Biological Standards and Quality Control and was a Deputy Director and Lab Chief in that Division, managing lot release of biological products, review of analytical methods for the biologics license applications, generation of reference standards and development of new methods. He worked at Wyeth, Chiron, FDA & NIH.
Dale Moss
Business, Marketing and Corporate Strategy
TurboVax Inc, Philadelphia, USA
A seasoned executive with 37 years of experience with British Airways and it’s subsidiaries. Originally joining the airline as a sales trainee in the US and later becoming the USA’s Executive Vice President. Subsequently becoming the first American Executive Director to be based in London, for Sales and Marketing leadership and management responsibility where focus was on Sales and Marketing initiatives and drove revenue and market share. Concluding the career with BA, was the founder and the first Chief Executive Officer of OpenSkies, a boutique premium point to point international airline, flying between Paris and New York.
Scotty McConnaughey
Portfolio Manager & Senior Equity Research Analyst Cambridge Trust Company
Graduated from Darthmouth College and Harvard University. For over 20 years analyzed stocks and managed equity portfolios for Fidelity Investments, Westfeild Capital Management,. Served as the Investment Director, U.S. Equities for Aberdeen Standard Investments. Served as operating partner for Ouroboros Group and Limited Partner for Six Trees Capital LLC. An accomplished investor with demonstrated history of generating alpha, fostering effective teams, and leading cross-functional projects.
Our Philosophy
At TurboVax, we believe that breakthrough vaccines emerge when fundamental scientific discovery is combined with experienced clinical, regulatory, and commercial leadership.
Our team shares a common mission: Advancing fundamental immunology into vaccines that improve human health.
Join Our Journey
TurboVax welcomes opportunities to collaborate with scientists, clinicians, industry leaders, investors, and organizations committed to advancing vaccine innovation.
Contact us to explore opportunities for partnership and collaboration.